Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
| Price | $30.20 |
|---|---|
| Market cap | $519,319 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 14.75-46.95 |
| Dividend (TTM) | $20.10 per share |
| Beta | 2.07 |
Explore YARW's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.